LONDON — T-Therapeutics has raised £48 million ($59 million) in a Series A round supported by a Big Pharma to discover and develop new T cell receptor (TCR) therapeutics using its transgenic mouse technology.
The round was co-led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and…
Click here to view original post
